These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36393907)

  • 1. Bilateral bullous central serous chorioretinopathy treated with PDT and eplerenone.
    Anderson WJ; Smith BT
    Am J Ophthalmol Case Rep; 2022 Dec; 28():101739. PubMed ID: 36393907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical Chronic Central Serous Chorioretinopathy Mimicking Vogt-Koyanagi-Harada Disease: Full Therapeutic Response to Half-Fluence Photodynamic Therapy.
    Yanık Ö; Batıoğlu F; Yalçındağ N; Demirel S; Özmert E
    Turk J Ophthalmol; 2022 Apr; 52(2):147-152. PubMed ID: 35481737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Half-dose verteporfin photodynamic therapy for bullous variant of central serous chorioretinopathy: a case report.
    Ng WW; Wu ZH; Lai TY
    J Med Case Rep; 2011 May; 5():208. PubMed ID: 21615893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone - a case report.
    Venkatesh R; Pereira A; Jain K; Yadav NK
    BMC Ophthalmol; 2020 Jun; 20(1):219. PubMed ID: 32503484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes of half-fluence photodynamic therapy and eplerenone in chronic central serous chorioretinopathy: A comparative study.
    Manayath G; Verghese S; Ranjan R; Agrawal H; Khanna A; Narendran V; Chhablani J
    Eur J Ophthalmol; 2021 Nov; 31(6):3110-3116. PubMed ID: 33508971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bullous Central Serous Chorioretinopathy: A Rare and Atypical Form of Central Serous Chorioretinopathy. A Systematic Review.
    Sartini F; Menchini M; Posarelli C; Casini G; Figus M
    Pharmaceuticals (Basel); 2020 Aug; 13(9):. PubMed ID: 32872388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Eplerenone in Chronic Central Serous Chorioretinopathy Refractory to Photodynamic Therapy.
    Karagiannis D; Parikakis E; Kontomichos L; Batsos G; Chatziralli I
    Semin Ophthalmol; 2019; 34(6):436-441. PubMed ID: 31309849
    [No Abstract]   [Full Text] [Related]  

  • 8. Surgical Treatment of Bullous Exudative Retinal Detachment Secondary to Atypical Bilateral Central Serous Chorioretinopathy.
    Özdemir HB; Yüksel M; Hasanreisoğlu M; Gürelik G; Sarıcı AM; Tuğal-Tutkun İ; Özdek Ş
    Turk J Ophthalmol; 2023 Dec; 53(6):395-398. PubMed ID: 38014882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial.
    Willcox A; Culliford L; Ellis L; Rogers CA; Cree A; Chakravarthy U; Ennis S; Behar-Cohen F; Reeves BC; Sivaprasad S; Lotery A
    Eye (Lond); 2019 Feb; 33(2):295-303. PubMed ID: 30194380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unilateral recurrent central serous chorioretinopathy (CSCR) following COVID-19 vaccination- A multimodal imaging study.
    Sanjay S; Acharya I; Kawali A; Shetty R; Mahendradas P
    Am J Ophthalmol Case Rep; 2022 Sep; 27():101644. PubMed ID: 35818570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scleral thinning surgery for bullous retinal detachment with retinal pigment epithelial tear in central serous chorioretinopathy: a case report.
    Maggio E; Mete M; Maraone G; Arena F; Pertile G
    BMC Ophthalmol; 2020 Apr; 20(1):133. PubMed ID: 32252699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential involvement of mineralocorticoid receptor activation in the pathogenesis of central serous chorioretinopathy: case report.
    Gruszka A
    Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1369-73. PubMed ID: 23740451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Half-Dose Photodynamic Therapy Versus Eplerenone in Chronic Central Serous Chorioretinopathy (SPECTRA): A Randomized Controlled Trial.
    van Rijssen TJ; van Dijk EHC; Tsonaka R; Feenstra HMA; Dijkman G; Peters PJH; Diederen RMH; Hoyng CB; Schlingemann RO; Boon CJF
    Am J Ophthalmol; 2022 Jan; 233():101-110. PubMed ID: 34214454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR).
    Rahimy E; Pitcher JD; Hsu J; Adam MK; Shahlaee A; Samara WA; Vander JF; Kaiser RS; Chiang A; Spirn MJ; Fineman MS
    Retina; 2018 May; 38(5):962-969. PubMed ID: 28426624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healing pattern of subfoveal retinal pigment epithelium rip and aperture in central serous chorioretinopathy.
    Manayath GJ; Khanna A; Ranjan R; Venkatapathy N
    Oman J Ophthalmol; 2023; 16(1):170-174. PubMed ID: 37007249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATYPICAL CENTRAL SEROUS CHORIORETINOPATHY WITH CHOROIDAL DETACHMENT: A CASE REPORT.
    Manayath GJ; Kuthirummal N; Ranjan R; Verghese S; Venkatapathy N
    Retin Cases Brief Rep; 2022 Nov; 16(6):735-739. PubMed ID: 33017379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical chronic central serous chorioretinopathy with cystoid macular edema: Therapeutic response to medical and laser therapy.
    Do JL; Olmos de Koo LC; Ameri H
    J Curr Ophthalmol; 2017 Jun; 29(2):133-135. PubMed ID: 28626824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine Clinical Practice Treatment Outcomes of Eplerenone in Acute and Chronic Central Serous Chorioretinopathy.
    Fasler K; Gunzinger JM; Barthelmes D; Zweifel SA
    Front Pharmacol; 2021; 12():675295. PubMed ID: 34040534
    [No Abstract]   [Full Text] [Related]  

  • 19. A Case of Bullous Central Serous Chorioretinopathy Treated with Surgical Removal of Submacular Fibrin and Subsequent Photodynamic Therapy under Silicone Oil.
    Notomi S; Shiose S; Kohno RI; Shimokawa S; Ishikawa K; Kano K; Mori K; Wada I; Fukuda Y; Nakatake S; Yamaguchi M; Sonoda KH
    Case Rep Ophthalmol; 2022; 13(2):385-392. PubMed ID: 35811763
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.